Autism Spectrum Disorder Treatment Market To Reach $4.40 Billion By 2033

Autism Spectrum Disorder Treatment Market Growth & Trends

The global autism spectrum disorder treatment market size is expected to reach USD 4.40 billion by 2033, registering a CAGR of 6.3% from 2026 to 2033, according to a new report by Grand View Research, Inc. Many of the experimental autism spectrum disorder (ASD) drugs in the academic studies and pharma pipeline are assessing important theories about how the genetic fingerprint and brain contribute to the development of autism. Some of the pipeline drugs include AB-2004 & AB-2004 PTR by Axial Therapeutics, Inc., Zygel by Zynerba Pharmaceuticals, Inc., and INP105 (Olanzapine) by Impel Pharmaceuticals Inc.

In July 2022, Impel Pharmaceuticals Inc. initiated the first patient dose in phase 2a study evaluating INP-105 to treat acute agitation in adolescents with autism spectrum disorder (ASD). The company uses its Precision Olfactory Delivery (POD) technology to deliver medicine to the upper nasal part and increase the absorption of the drug, without the need for injection. Thus, technological advancement in drug delivery is anticipated to drive the market.

In May 2020, HARMAN International and F. Hoffmann-La Roche Ltd. entered into a global partnership to develop a digital therapeutic platform for individuals with ASD. Under this partnership, Harman and Samsung combined their extensive technology with F. Hoffmann-La Roche Ltd.’s leadership in neuroscience to develop innovative therapies for the treatment of ASD.

Rising awareness and funding for research and development of autism spectrum disorder are expected to positively contribute to the growth of the market. For instance, the Sapienza Università di Roma every year celebrates the 2^nd of April as ‘World Autism Awareness Day’ with an aim to increase awareness about the disease and its treatment benefits among physicians and patients. Furthermore, in November 2022, the Defiance County Board of Developmental Disabilities/Good Samaritan School and the Andrew Jimenez Autism Fund received a donation of USD 1000 from Buckeye Roofing and Exteriors owner to support the efforts to raise awareness about ASD, subsequently creating an opportunity for the market growth.

 Request a free sample copy or view report summary: Autism Spectrum Disorder Treatment Market Report

Autism Spectrum Disorder Treatment Market Report Highlights

• By type, the antipsychotic drugs segment dominated the market with the largest revenue share of 40.9% in 2025 and is expected to grow at the fastest CAGR during the forecast period.

• Based on application, the autistic disorder segment dominated the market with the largest revenue share of 63.9% in 2025 and is expected to grow at the fastest CAGR during the forecast period.

• By distribution channel, the retail pharmacies held the highest market share of 69.6% in 2025. The online pharmacies segment is projected to grow at a CAGR of 7.4% over the forecast period.

• North America autism spectrum disorder treatment market held the largest share of 51.8% in 2025. The autism spectrum disorder treatment market in the U.S. accounted for the largest share within North America in 2025.

• The autism spectrum disorder treatment market in Asia Pacific is expected to register the fastest CAGR of 8.1% over the forecast period due to improving healthcare accessibility, increasing autism awareness campaigns, and rising investment in pediatric neurodevelopmental care across developing and developed economies.

Autism Spectrum Disorder Treatment Market Segmentation

Grand View Research has segmented global autism spectrum disorder treatment market report based on type, application, distribution channel, and region:

Autism Spectrum Disorder Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)

• Antipsychotic Drugs

• Selective Serotonin Reuptake Inhibitors

• Stimulants

• Sleep Medications

• Others

Autism Spectrum Disorder Treatment Application Outlook (Revenue, USD Million, 2021 - 2033)

• Autistic Disorder

• Asperger Syndrome

• Pervasive Developmental Disorder

• Others

Autism Spectrum Disorder Treatment Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Autism Spectrum Disorder Treatment Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Autism Spectrum Disorder Treatment Market

• Curemark LLC

• Bristol-Myers Squibb Company

• Merck & Co., Inc.

• Novartis AG

• Eli Lilly and Company

• Pfizer Inc.

• Johnson & Johnson Services Inc.

• Otsuka Pharmaceutical Co., Ltd.

• Yamo Pharmaceuticals

• F.Hoffmann-La Roche Ltd.

• Axial Therapeutics Inc.